EVLVW — Evolv Technologies Holdings, Inc.

Summary of Evolv Technology Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Q4 Revenue: $38.5 million, up 32% year-over-year.
• Full Year Revenue: $145.9 million, reflecting a 40% increase year-over-year.
• Annual Recurring Revenue (ARR): $120.5 million, a 21% increase year-over-year.
• Adjusted EBITDA: Positive $1.8 million in Q4, with a margin of 4.7%. Full year adjusted EBITDA was $11.1 million, up from a loss of $21 million in 2024.
• Remaining Performance Obligation (RPO): $293.4 million, a 13% increase year-over-year.
• Cash Position: Increased by $12.8 million sequentially to $69 million.

2. Strategic Updates and Business Highlights:

• Evolv has deployed 8,000 systems screening over 4 million people daily, with a total of over 1,200 customers.
• The company continues to enhance its product offerings, including the Gen2 Express platform and the new eXpedite autonomous bag screening solution, which has gained traction with 65 customers.
• Significant customer wins included partnerships with over 60 new customers in Q4, including schools, healthcare facilities, and sports organizations.
• Evolv has been designated as a preferred provider for hospitals by the American Hospital Association, which is expected to drive further growth in the healthcare sector.

3. Forward Guidance and Outlook:

• For 2026, Evolv expects revenue between $172 million and $178 million, an increase from previous guidance of $160 million to $165 million, representing year-over-year growth of approximately 18% to 22%.
• ARR growth is projected to be between 20% to 25%, with expectations of over 10,000 units deployed by year-end.
• Adjusted EBITDA margins are anticipated to expand into the high single digits.

4. Bad News, Challenges, or Points of Concern:

• Gross Margin Decline: Adjusted gross margin fell to 50% in Q4 from 62% year-over-year, attributed to a shift to direct fulfillment and a $1 million accrual for service costs.
• Subscription Revenue Timing: A short-term subscription contract related to a major sporting event impacted subscription revenue in Q4.
• Operational Costs: The company faces a headwind from increased memory chip costs, which may affect margins.

5. Notable Q&A Insights:

• The management indicated that they expect ARR growth to accelerate throughout 2026, driven by changes in pricing and fulfillment models.
• The mix of new customer acquisitions versus existing customer expansions remains balanced at approximately 50-50.
• The partnership with Plexus is expected to ramp up production in the second half of 2026, potentially improving gross margins and operational efficiency.
• Management emphasized a commitment to responsible growth, ensuring that revenue increases outpace expense growth, which is reflected in their adjusted EBITDA margin expansion strategy.

Overall, Evolv Technology demonstrated strong growth in Q4 2025 and provided an optimistic outlook for 2026, despite facing some challenges related to gross margins and operational costs.